Brief: Sorrento Recieves FDA Clearance For Commencement Of Study For Abivertinib In Hospitalized Patients With Severe Pneumonia Due To COVID-19
31/03/2022 14:08
March 31 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO REPORTS FDA CLEARANCE FOR COMMENCEMENT OF A PHASE
2/3
STUDY FOR ABIVERTINIB IN TREATMENT OF HOSPITALIZED PATIENTS WITH
SEVERE PNEUMONIA DUE TO COVID-19
Source text for Eikon: ID:nGNX1LQpwR
Further company coverage: SRNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20